EMBC Stock Overview
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.62 |
| 52 Week High | US$19.79 |
| 52 Week Low | US$9.93 |
| Beta | 0.94 |
| 11 Month Change | 7.18% |
| 3 Month Change | 7.74% |
| 1 Year Change | -10.47% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
Nov 07
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Sep 24Recent updates
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
Nov 07It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Sep 24Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Aug 16Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Aug 14When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
Jul 13Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 12Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
Feb 21Embecta Corp.'s (NASDAQ:EMBC) Prospects Need A Boost To Lift Shares
Jul 16Embecta Corp. (NASDAQ:EMBC) Shares Could Be 37% Below Their Intrinsic Value Estimate
Mar 30Embecta Corp. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 17Embecta: Comments On 2nd Earnings Since Spin Off
Sep 04Some Investors May Be Willing To Look Past Embecta's (NASDAQ:EMBC) Soft Earnings
Aug 23Embecta GAAP EPS of $1.07 beats by $0.20, revenue of $291.1M beats by $14.24M
Aug 15Embecta Is A Winner In A Growing Market
Jun 07Shareholder Returns
| EMBC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.3% | -1.2% | -2.1% |
| 1Y | -10.5% | 22.4% | 29.6% |
Return vs Industry: EMBC underperformed the US Medical Equipment industry which returned 22.8% over the past year.
Return vs Market: EMBC underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| EMBC volatility | |
|---|---|
| EMBC Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMBC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EMBC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 2,200 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
Embecta Corp. Fundamentals Summary
| EMBC fundamental statistics | |
|---|---|
| Market cap | US$843.60m |
| Earnings (TTM) | US$69.70m |
| Revenue (TTM) | US$1.12b |
12.1x
P/E Ratio0.8x
P/S RatioIs EMBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBC income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$375.70m |
| Gross Profit | US$743.20m |
| Other Expenses | US$673.50m |
| Earnings | US$69.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 66.42% |
| Net Profit Margin | 6.23% |
| Debt/Equity Ratio | -209.5% |
How did EMBC perform over the long term?
See historical performance and comparison